This is the authors' abstract. We don't add key points for this paper.
Background.Elevated ACE expression in tissues (reflected by blood ACE levels) is associated with increased risk of cardiovascular diseases and is a marker for granulomatous diseases. We developed a new approach for characterization of ACE status in the blood - ACE phenotyping - and established normal values of ACE levels as 50–150% of control pooled plasma.Methods.ACE phenotyping was performed in citrated plasma of 120 patients with known interstitial lung diseases and included 1) simultaneous determination of ACE activity with 2 substrates (ZPHL and HHL); 2) calculation of the ratio of hydrolysis of two substrates (ZPHL/HHL ratio); 3) determination of the levels of ACE immunoreactive protein and ACE conformation with a set of monoclonal antibodies (mAbs) to ACE.Results.In the 1st set of 100 patients, 22 patients had ACE levels > 150%; ACE phenotyping also objectively identified the presence of ACE inhibitors in the plasma of 15 patients. After excluding these patients and one other patient with ACE mutation that increases ACE shedding, 17 patients were identified as a suspicious for systemic sarcoidosis based on elevation of blood ACE (> 150% of mean). Our newly established parameter–ACE immunoreactivity (with mAb 9B9)—allowed us to detect 22 patients with decreased values (< 80%) of this parameter, which may indicate the presence of ACE in the blood that originates from macrophages/dendritic cells of granulomas. In the remaining 20 patients, this new parameter (mAbs binding/activity ratio) was calculated using 3 mAbs (9B9, 3A5 and i1A8 - having overlapping epitopes), and 8 patients were identified as having decreased levels, thus increasing dramatically the sensitivity for detection of patients with systemic sarcoidosis. Whole body PET scan confirmed extrapulmonary granulomas in some patients with lower immunoreactivity towards anti-ACE mAbs.Conclusions.These results demonstrate that ACE phenotyping has novel potential to noninvasively detect patients with systemic sarcoidosis.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Danilov et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: